Medical Device 510(k) Success
How MedTech Innovations achieved FDA 510(k) clearance in 90 days versus the 180-day industry average, accelerating their market entry and saving significant costs.
- 90 Days
- To FDA Clearance
- $125,000
- Total Savings
- 280%
- Return on Investment
The Client
MedTech Innovations is a venture-backed medical device company developing innovative diagnostic equipment for point-of-care testing. Their flagship product, a portable blood analyzer, was poised to disrupt the traditional laboratory testing model.
Company Profile
- Stage:
- Series B ($28M raised)
- Device Class:
- Class II
- Pathway:
- 510(k)
- Employees:
- 45
The Challenge
MedTech had completed product development and clinical testing but faced pressure from investors to achieve FDA clearance quickly. Their initial 510(k) submission attempt, prepared internally, had received an Additional Information (AI) request that threatened to delay clearance by 6+ months.
Critical Challenges
- •FDA AI request identified 15 deficiencies in submission
- •Predicate device selection was questioned by reviewers
- •Performance testing data presentation was inadequate
- •Software documentation did not meet FDA expectations
- •Investor milestone deadline in 120 days
The Solution
We assembled a team of regulatory specialists, including a former FDA reviewer, to rescue the submission and get it back on track:
Week 1-2: Comprehensive Assessment
- Complete review of original 510(k) submission (21 CFR Part 807 Subpart E) and the FDA's Additional Information request, which cited 15 specific deficiencies
- Gap analysis of performance testing data vs. FDA expectations under the applicable recognized consensus standards
- Evaluation of predicate device strategy -- the original submission used a single predicate that FDA reviewers questioned due to significant technological differences. Our team identified two alternative predicates using FDA's 510(k) Premarket Notification Database and AccessGUDID
- Scheduled and conducted a Pre-Submission (Q-Sub) meeting with FDA under the Q-Sub program guidance to clarify acceptance criteria before revising the submission
Week 3-6: Submission Restructure
- Developed a split-predicate strategy using two cleared predicates, each covering different technological characteristics -- this approach provided a stronger substantial equivalence argument by comparing each feature to the most appropriate predicate
- Restructured performance data presentation with clear comparison tables following the FDA-recommended "side-by-side comparison" format from the 510(k) Program guidance
- Rewrote software documentation to align with FDA's "Guidance for the Content of Premarket Submissions for Device Software Functions" including software level of concern determination, hazard analysis, and verification/validation evidence
- Added missing biocompatibility testing documentation per ISO 10993-1 for patient-contacting components, including cytotoxicity, sensitization, and irritation testing reports
Week 7-8: AI Response Preparation
- Drafted comprehensive responses to all 15 deficiencies with cross-references to supporting evidence throughout the submission package
- Internal quality review by our team including a former CDRH reviewer who validated the response strategy and supporting evidence against current FDA reviewer expectations
- Final submission assembly following eCopy/eSTAR format requirements, QC check against FDA Refuse to Accept checklist, and dry-run review
- Submitted complete AI response package electronically -- received clearance with no additional questions
The Results
90-Day Clearance
Achieved 510(k) clearance in 90 days from our engagement vs. 180-day average. No additional AI requests.
Cost Savings
$125,000 total savings from accelerated timeline, avoided resubmission, and reduced internal resource allocation.
Investor Milestone Met
FDA clearance achieved 30 days before investor deadline, preserving $5M Series C funding milestone.
Market Leadership
Entered market 3 months ahead of primary competitor who was pursuing similar device clearance.
Regulatory Framework Applied
- Clearance Pathway:
- 510(k) -- 21 CFR Part 807 Subpart E
- Device Classification:
- Class II (Special Controls)
- FY2026 510(k) Review Fee:
- $26,067 (standard) / $6,517 (small business)
- Establishment Registration:
- $11,423/year (FY2026 MDUFA)
- Software Guidance:
- Content of Premarket Submissions for Software
- Biocompatibility:
- ISO 10993-1
Important: QMSR Transition (Effective February 2, 2026)
The FDA's Quality Management System Regulation (QMSR) takes effect on February 2, 2026, replacing the current Quality System Regulation (QSR, 21 CFR Part 820). Medical device manufacturers must now comply with the QMSR framework, which incorporates ISO 13485:2016 by reference. If you are pursuing 510(k) clearance in 2026, your quality system documentation should reflect QMSR requirements. MedTech Innovations completed their quality system transition ahead of the deadline with Assurentry's guidance.
Timeline Comparison
510(k) Clearance Timeline
ROI Analysis
| Category | Savings |
|---|---|
| 90 days faster market entry (revenue opportunity) | $75,000 |
| Avoided resubmission costs | $25,000 |
| Reduced internal regulatory staff time | $25,000 |
| TOTAL VALUE | $125,000 |
| Assurentry engagement | $35,000 |
| NET ROI | 280% |
"When we received that AI request, our hearts sank. We thought we had done everything right, but clearly we hadn't. Assurentry's team didn't just fix the problems - they rebuilt our submission into something FDA could say yes to. The fact that we got clearance faster than the industry average, after starting with a failed submission, is remarkable."
Navigating the 510(k) Process?
Whether you're preparing an initial submission or responding to an AI request, our team of device regulatory experts can help you achieve clearance efficiently.